Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Net Margin (2018 - 2025)

BioNexus Gene Lab's Net Margin history spans 8 years, with the latest figure at 214.18% for Q4 2025.

  • Quarterly results put Net Margin at 214.18% for Q4 2025, down 20038.0% from a year ago — trailing twelve months through Dec 2025 was 40.2% (down 2339.0% YoY), and the annual figure for FY2025 was 40.2%, down 2339.0%.
  • Net Margin for Q4 2025 was 214.18% at BioNexus Gene Lab, down from 27.87% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 15.46% in Q4 2023 to a low of 214.18% in Q4 2025.
  • The 5-year median for Net Margin is 4.87% (2024), against an average of 22.41%.
  • The sharpest move saw Net Margin skyrocketed 5103bps in 2024, then crashed -20038bps in 2025.
  • Year by year, Net Margin stood at 3.57% in 2021, then crashed by -251bps to 5.39% in 2022, then surged by 387bps to 15.46% in 2023, then tumbled by -189bps to 13.8% in 2024, then plummeted by -1452bps to 214.18% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 214.18%, 27.87%, and 27.26% for Q4 2025, Q3 2025, and Q2 2025 respectively.